Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Guirnalda, Patrick ^a,b   Wood, Laurence ^a,c   Goenka, Radhika ^a   Crespo, Joel ^a,d   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chemokine; IFN receptor; Immunotherapy; Listeria monocytogenes; T cells; Tumor

Indexed keywords

CANCER VACCINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LISTERIOLYSIN O E7 VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR; T LYMPHOCYTE SUBPOPULATION;

EID: 84885695213     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25752     Document Type: Article

References (36)

1. Hussain SF, Paterson Y. What is needed for effective antitumor immunotherapyγ Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. [doi]. Cancer Immunol Immunother 2005; 54:577-86; PMID:15650885; http://dx.doi.org/10.1007/s00262-004-0600-2
2. Peng X, Hussain SF, Paterson Y. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol 2004; 172:6030-8; PMID:15128786
3. Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. [doi]. Cancer Immunol Immunother 2005; 54:477-88; PMID:15750832; http://dx.doi.org/10.1007/s00262-004-0610-0
4. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167:6471-9; PMID:11714814
5. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011; 317:620-31; PMID:21376175; http:// dx.doi.org/10.1016/j.yexcr.2010.12.017
6. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996; 93:13791-6; PMID:8943014; http://dx.doi.org/10.1073/ pnas.93.24.13791
7. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997; 89:2635-43; PMID:9108380
8. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 2007; 178:2278-86; PMID:17277133
9. Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS, et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001; 61:8498-503; PMID:11731434
10. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161:927-32; PMID:9670971
11. Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA, et al. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002; 62:2606-10; PMID:11980656
12. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000; 164:3112-22; PMID:10706701
13. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, et al. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by singlechain IL-12 gene therapy. J Immunol 2001; 166:6944-51; PMID:11359856
14. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89:207-15; PMID:21221121; http:// dx.doi.org/10.1038/icb.2010.158
15. -kB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012; 72:3735-43; PMID:22593190; http://dx.doi. org/10.1158/0008-5472.CAN-11-4136
16. Guirnalda P, Paterson Y. Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17+ γd T cells in a murine model for HPV associated cancer. OncoImmunology 2012; 1:822-828; http://dx.doi. org/10.4161/onci.20491
17. Carr DJ, Wuest T, Ash J. An increase in herpes simplex virus type 1 in the anterior segment of the eye is linked to a deficiency in NK cell infiltration in mice deficient in CXCR3. [doi]. J Interferon Cytokine Res 2008; 28:245-51; PMID:18439102; http://dx.doi. org/10.1089/jir.2007.0110
18. Raitano AB, Scuderi P, Korc M. Upregulation of interferon-gamma binding by tumor necrosis factor and lymphotoxin: disparate potencies of the cytokines and modulation of their effects by phorbol ester. J Interferon Res 1991; 11:61-7; PMID:1903142; http:// dx.doi.org/10.1089/jir.1991.11.61
19. Raitano AB, Korc M. Tumor necrosis factor upregulates gamma-interferon binding in a human carcinoma cell line. J Biol Chem 1990; 265:10466-72; PMID:2141333
20. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97:780-6; PMID:16863511; http://dx.doi. org/10.1111/j.1349-7006.2006.00231.x
21. + T-cell recruitment. Cancer Res 2009; 69:3077-85; PMID:19293190; http://dx.doi.org/10.1158/0008-5472.CAN-08-2281
22. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40; PMID:19909745; http://dx.doi. org/10.1053/j.gastro.2009.10.057
23. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71 (22):6997-7009
24. Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gammainducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002; 217:12-22; PMID:12425997; http://dx.doi.org/10.1016/S0008-8749(02)00508-7.
25. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27:3975-83; PMID:19389451; http://dx.doi. org/10.1016/j.vaccine.2009.04.041
26. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765
27. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988; 48:2975-80; PMID:3259156
28. Murphy GP, Hrushesky WJ. A murine renal cell carcinoma. J Natl Cancer Inst 1973; 50:1013-25; PMID:4703766
29. Beatty GL, Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by downregulating cellular levels of an endogenous tumor antigen. J Immunol 2000; 165:5502-8; PMID:11067903
30. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60:3569-76; PMID:10910070
31. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405; PMID:1540948
32. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; Chapter 20:Unit 20 22. http://dx.doi.org/.1002/0471142735. im2002s39
33. Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, Xiang ZQ, Giles-Davis W, Ertl HC. A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods 2001; 253:163-75; PMID:11384678; http://dx.doi.org/10.1016/S0022-1759(01)00356-8
34. Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000; 60:2136-9; PMID:10786675
35. Krawczyk CM, Shen H, Pearce EJ. Memory CD4 T cells enhance primary CD8 T-cell responses. Infect Immun 2007; 75:3556-60; PMID:17438031; http:// dx.doi.org/10.1128/IAI.00086-07
36. Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancerassociated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991; 88:5887-91; PMID:1712110; http://dx.doi.org/10.1073/pnas.88.13.5887